Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

Victor R. Grann, Priya R. Patel, Judith S. Jacobson, Ellen Warner, Daniel F. Heitjan, Maxine Ashby-Thompson, Dawn L. Hershman, Alfred I. Neugut

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Comparative effectiveness research has become an integral part of health care planning in most developed countries. In a simulated cohort of women, aged 30-65, who tested positive for BRCA1 or BRCA2 mutations, we compared outcomes of mammography with and without MRI, prophylactic oophorectomy with and without mastectomy, mastectomy alone, and chemoprevention. Methods: Using Treeage 9.02 software, we developed Markov models with 25,000 Monte Carlo simulations and conducted probabilistic sensitivity analysis. We based mutation penetrance rates, breast and ovarian cancer incidence, and mortality rates, and costs in terms of 2009 dollars, on published studies and data from the Surveillance, Epidemiology, and End Results (SEER) Program and the Centers for Medicare and Medicaid Services. We used preference ratings obtained from mutation carriers and controls to adjust survival for quality of life (QALYs). Results: For BRCA1 mutation carriers, prophylactic oophorectomy at $1,741 per QALY, was more cost effective than both surgeries and dominated all other interventions. For BRCA2 carriers, prophylactic oophorectomy, at $4,587 per QALY, was more cost effective than both surgeries. Without quality adjustment, both mastectomy and BSO surgeries dominated all other interventions. In all simulations, preventive surgeries or chemoprevention dominated or were more cost effective than screening because screening modalities were costly. Conclusion: Our analysis suggested that among BRCA1/2 mutation carriers, prophylactic surgery would dominate or be cost effective compared to chemoprevention and screening. Annual screening with MRI and mammography was the most effective strategy because it was associated with the longest quality-adjusted survival, but it was also very expensive.

Original languageEnglish (US)
Pages (from-to)837-847
Number of pages11
JournalBreast Cancer Research and Treatment
Volume125
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Quality-Adjusted Life Years
Mastectomy
Chemoprevention
Costs and Cost Analysis
Ovariectomy
Mutation
Mammography
Comparative Effectiveness Research
SEER Program
Centers for Medicare and Medicaid Services (U.S.)
Health Planning
Survival
Penetrance
Mutation Rate
Developed Countries
Ovarian Neoplasms
Software
Quality of Life
Breast Neoplasms
Delivery of Health Care

Keywords

  • BRCA1/BRCA2
  • Comparative effectiveness
  • Cost-effectiveness
  • Mastectomy
  • Oophorectomy or both
  • Screening with MRI and mammography
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. / Grann, Victor R.; Patel, Priya R.; Jacobson, Judith S.; Warner, Ellen; Heitjan, Daniel F.; Ashby-Thompson, Maxine; Hershman, Dawn L.; Neugut, Alfred I.

In: Breast Cancer Research and Treatment, Vol. 125, No. 3, 01.02.2011, p. 837-847.

Research output: Contribution to journalArticle

Grann, VR, Patel, PR, Jacobson, JS, Warner, E, Heitjan, DF, Ashby-Thompson, M, Hershman, DL & Neugut, AI 2011, 'Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers', Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 837-847. https://doi.org/10.1007/s10549-010-1043-4
Grann, Victor R. ; Patel, Priya R. ; Jacobson, Judith S. ; Warner, Ellen ; Heitjan, Daniel F. ; Ashby-Thompson, Maxine ; Hershman, Dawn L. ; Neugut, Alfred I. / Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. In: Breast Cancer Research and Treatment. 2011 ; Vol. 125, No. 3. pp. 837-847.
@article{e741aca2b90b4238aaab2105ad13d6d6,
title = "Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers",
abstract = "Comparative effectiveness research has become an integral part of health care planning in most developed countries. In a simulated cohort of women, aged 30-65, who tested positive for BRCA1 or BRCA2 mutations, we compared outcomes of mammography with and without MRI, prophylactic oophorectomy with and without mastectomy, mastectomy alone, and chemoprevention. Methods: Using Treeage 9.02 software, we developed Markov models with 25,000 Monte Carlo simulations and conducted probabilistic sensitivity analysis. We based mutation penetrance rates, breast and ovarian cancer incidence, and mortality rates, and costs in terms of 2009 dollars, on published studies and data from the Surveillance, Epidemiology, and End Results (SEER) Program and the Centers for Medicare and Medicaid Services. We used preference ratings obtained from mutation carriers and controls to adjust survival for quality of life (QALYs). Results: For BRCA1 mutation carriers, prophylactic oophorectomy at $1,741 per QALY, was more cost effective than both surgeries and dominated all other interventions. For BRCA2 carriers, prophylactic oophorectomy, at $4,587 per QALY, was more cost effective than both surgeries. Without quality adjustment, both mastectomy and BSO surgeries dominated all other interventions. In all simulations, preventive surgeries or chemoprevention dominated or were more cost effective than screening because screening modalities were costly. Conclusion: Our analysis suggested that among BRCA1/2 mutation carriers, prophylactic surgery would dominate or be cost effective compared to chemoprevention and screening. Annual screening with MRI and mammography was the most effective strategy because it was associated with the longest quality-adjusted survival, but it was also very expensive.",
keywords = "BRCA1/BRCA2, Comparative effectiveness, Cost-effectiveness, Mastectomy, Oophorectomy or both, Screening with MRI and mammography, Tamoxifen",
author = "Grann, {Victor R.} and Patel, {Priya R.} and Jacobson, {Judith S.} and Ellen Warner and Heitjan, {Daniel F.} and Maxine Ashby-Thompson and Hershman, {Dawn L.} and Neugut, {Alfred I.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s10549-010-1043-4",
language = "English (US)",
volume = "125",
pages = "837--847",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

AU - Grann, Victor R.

AU - Patel, Priya R.

AU - Jacobson, Judith S.

AU - Warner, Ellen

AU - Heitjan, Daniel F.

AU - Ashby-Thompson, Maxine

AU - Hershman, Dawn L.

AU - Neugut, Alfred I.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Comparative effectiveness research has become an integral part of health care planning in most developed countries. In a simulated cohort of women, aged 30-65, who tested positive for BRCA1 or BRCA2 mutations, we compared outcomes of mammography with and without MRI, prophylactic oophorectomy with and without mastectomy, mastectomy alone, and chemoprevention. Methods: Using Treeage 9.02 software, we developed Markov models with 25,000 Monte Carlo simulations and conducted probabilistic sensitivity analysis. We based mutation penetrance rates, breast and ovarian cancer incidence, and mortality rates, and costs in terms of 2009 dollars, on published studies and data from the Surveillance, Epidemiology, and End Results (SEER) Program and the Centers for Medicare and Medicaid Services. We used preference ratings obtained from mutation carriers and controls to adjust survival for quality of life (QALYs). Results: For BRCA1 mutation carriers, prophylactic oophorectomy at $1,741 per QALY, was more cost effective than both surgeries and dominated all other interventions. For BRCA2 carriers, prophylactic oophorectomy, at $4,587 per QALY, was more cost effective than both surgeries. Without quality adjustment, both mastectomy and BSO surgeries dominated all other interventions. In all simulations, preventive surgeries or chemoprevention dominated or were more cost effective than screening because screening modalities were costly. Conclusion: Our analysis suggested that among BRCA1/2 mutation carriers, prophylactic surgery would dominate or be cost effective compared to chemoprevention and screening. Annual screening with MRI and mammography was the most effective strategy because it was associated with the longest quality-adjusted survival, but it was also very expensive.

AB - Comparative effectiveness research has become an integral part of health care planning in most developed countries. In a simulated cohort of women, aged 30-65, who tested positive for BRCA1 or BRCA2 mutations, we compared outcomes of mammography with and without MRI, prophylactic oophorectomy with and without mastectomy, mastectomy alone, and chemoprevention. Methods: Using Treeage 9.02 software, we developed Markov models with 25,000 Monte Carlo simulations and conducted probabilistic sensitivity analysis. We based mutation penetrance rates, breast and ovarian cancer incidence, and mortality rates, and costs in terms of 2009 dollars, on published studies and data from the Surveillance, Epidemiology, and End Results (SEER) Program and the Centers for Medicare and Medicaid Services. We used preference ratings obtained from mutation carriers and controls to adjust survival for quality of life (QALYs). Results: For BRCA1 mutation carriers, prophylactic oophorectomy at $1,741 per QALY, was more cost effective than both surgeries and dominated all other interventions. For BRCA2 carriers, prophylactic oophorectomy, at $4,587 per QALY, was more cost effective than both surgeries. Without quality adjustment, both mastectomy and BSO surgeries dominated all other interventions. In all simulations, preventive surgeries or chemoprevention dominated or were more cost effective than screening because screening modalities were costly. Conclusion: Our analysis suggested that among BRCA1/2 mutation carriers, prophylactic surgery would dominate or be cost effective compared to chemoprevention and screening. Annual screening with MRI and mammography was the most effective strategy because it was associated with the longest quality-adjusted survival, but it was also very expensive.

KW - BRCA1/BRCA2

KW - Comparative effectiveness

KW - Cost-effectiveness

KW - Mastectomy

KW - Oophorectomy or both

KW - Screening with MRI and mammography

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=79151485832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151485832&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1043-4

DO - 10.1007/s10549-010-1043-4

M3 - Article

C2 - 20644999

AN - SCOPUS:79151485832

VL - 125

SP - 837

EP - 847

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -